Back to results
US 10,894,036 B2Granted
Use of marizomib for the treatment of central nervous system (CNS) cancers
AssigneeCelgene International II SÀRL
InventorsMohit Trikha, Ann MacLaren, Nancy Levin
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
Claims9
A method of treating a CNS-cancer comprising administering to a subject in need thereof an effective amount of marizomib and bevacizumab;
- wherein the subject has a level of 06-methylguanine-DNA methyltransferase promoter methylation of 8% or less, and
- wherein the EGFR status of the patient is normal.
Dependencies are inferred from the claim text.